- Larry Busacca/Getty
Theranos has had a tough July.
Earlier in the month, the company revealed that its CEO, Elizabeth Holmes, had been barred from the lab-testing industry for two years, putting in doubt the future of the blood-testing startup that was once worth $9 billion.
But the company is making some hires that could help it keep from falling even further from grace.
Theranos announced Thursday that it had added two new positions to its staff, both reporting up to Holmes:
Daniel Guggenheim, a health lawyer who most recently worked at McKesson as assistant general counsel, will serve as the chief compliance officer, while Dave Wurtz will come in as vice president of regulatory and quality. Wurtz, who comes from the life-sciences company Thermo Fisher Scientific, will be in charge of Theranos’ submissions to the Food and Drug Administration (which, after the company got FDA approval for its herpes test in July 2015, haven’t advanced much in the past year).
Guggenheim will oversee the day-to-day of Theranos’ compliance programs.
Theranos also said in a release that it was creating a compliance and quality committee that will be headed by Fabrizio Bonanni, who joined the board of directors in May 2015 upon the departure of Theranos’ then-president and chief operating officer Sunny Balwani.
“I want to see the normal, serious work that needs to be done to effect the transformation of the company from an R&D startup to an operating company in the healthcare field,” Bonanni told Bloomberg‘s Caroline Chen.
The company still has plans to present its scientific data in an education session at a medical conference in August, when Theranos will have to show whether its technology is as revolutionary as it seems.